Document:

Exhibit 10.1

 

EMPLOYMENT
AGREEMENT

 

This Employment Agreement (the “Agreement”)
is entered into as of March 26, 2019 by and between Phio Pharmaceuticals Corp. (the “Company”), a Delaware corporation,
and John Barrett, Ph.D., (the “Executive”), an individual and resident of the State of Massachusetts.

 

1.       Employment.
Subject to the terms and conditions set forth in this Agreement, the Company hereby offers, and the Executive hereby accepts, employment
as the Company’s Chief Development Officer.

 

2.       Term.The Executive’s
employment shall commence on April 22, 2019, the Effective Date (the “Effective Date”), and shall continue until terminated
pursuant to Section 5 hereof (the “Term”).

 

3.       Capacity
and Performance.

 

(a)       During
the Term, the Executive shall be employed by the Company on a full-time basis and shall perform the duties and responsibilities
of his position and such other duties and responsibilities on behalf of the Company and its Affiliates as may be reasonably designated
from time to time by the Board of Directors of the Company (the “Board”) or by its chairman or other designee. The
Executive’s office shall be located at the Company’s principal place of business.

 

(b)       During
the Term, the Executive shall devote his full business time and his best efforts, business judgment, skill and knowledge exclusively
to the advancement of the business and interests of the Company and its Affiliates and to the discharge of his duties and responsibilities
hereunder. The Executive shall not engage in any other business activity or serve in any industry, trade, professional, governmental
or academic position during the Term, except as may be expressly approved in advance by the Board in writing. Notwithstanding the
foregoing, the Executive may serve on the boards of directors of other companies that are not Competitive (the “Other Boards”);
provided that: (i) commencing three months after the Effective Date, the Executive may serve on no more than three Other Boards;
and (ii) commencing six months after the Effective Date, the Executive may serve on no more than two Other Boards.

 

4.       Compensation
and Benefits. As compensation for all services performed by the Executive during the Term and subject to the Executive’s
performance of his duties and obligations to the Company and its Affiliates, pursuant to this Agreement or otherwise, the Company
shall provide the Executive with the following compensation and benefits:

 

(a)       Base
Salary and Bonus.

 

(i)       During
the Term, the Company shall pay the Executive a base salary at the rate of $315,000 per annum, payable in accordance with the payroll
practices of the Company for its executives and subject to adjustment from time to time by the Board, in its sole discretion, subject
to the Executive’s rights under Section 5(e)(ii) (such base salary, as from time to time adjusted, the “Base Salary”).

 

(ii)       The
Executive shall be eligible to receive an annual performance bonus, to be awarded at the discretion of the Compensation Committee
of the Board (the “Compensation Committee”), for the achievement of certain Company and Executive performance goals,
which goals will be established annually by the Compensation Committee. The target bonus for achieving these goals shall be equal
to thirty (30%) percent of the Base Salary.

 

(b)       Stock
Awards.

 

Initial Inducement Restricted
Stock Unit Award. On the Effective Date the Company shall grant to the Executive a Restricted Stock Unit award as an inducement
material to Executive’s entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Restricted
Stock Unit Award shall give the Executive the conditional right to receive 222,991 shares of common stock of the Company (the “Initial
Award”), without payment. The Initial Award shall become vested in equal annual installments over four (4) years beginning
on the first anniversary of the Effective Date of the Agreement; provided, in each case, that the Executive remains in the employ
of the Company through each such annual vesting date. The Initial Award shall be subject to such additional terms and conditions
as shall be set forth in an award agreement.

 

 

 

    	 	1	 

     

    

 

(ii)       Discretionary
Grants. In addition to the Initial Award contemplated under Section 4 (b)(i), at the sole discretion of the Compensation Committee,
Executive shall be eligible for additional grants of other equity awards.

 

(c)       Paid
Time Off. During the Term, the Executive shall be entitled to earn paid time off at the rate of 20 days per year. Paid time
off, which may be taken for any reason including vacation, sick leave and personal leave, may be taken at such times and intervals
as shall be determined by the Executive, subject to the reasonable business needs of the Company. Paid time off shall otherwise
be governed by the policies of the Company, as in effect from time to time. The number of paid “time off” days will
accrue per pay period and will stop accruing once 20 days have been accrued (with such accrual to recommence once the number of
paid “time off” days accrued by the Executive drops below 20 days). The Executive may take paid time off even if his
number of accrued paid time off days is insufficient to cover such days, so long as the Executive’s negative paid time off
balance does not exceed a balance of 7 days. Notwithstanding the foregoing, in the event that the Executive’s employment
is terminated while the Executive has a negative time off balance, the Executive shall be liable to the Company for the value of
such negative balance, which may be deducted from his Final Compensation.

 

(d)       Other
Benefits. During the term hereof, the Executive shall be entitled to participate in any and all employee benefit plans from
time to time in effect for employees of the Company generally, except to the extent any such employee benefit plan is in a category
of benefit otherwise provided to the Executive (e.g., a severance pay plan). Such participation shall be subject to the terms of
the applicable plan documents and generally applicable Company policies. The Company may alter, modify, add to or delete its employee
benefit plans at any time as it, in its sole judgment, determines to be appropriate, without recourse by the Executive.

 

(e)       Business
Expenses. The Company shall pay or reimburse the Executive for all reasonable and necessary business expenses incurred or paid
by the Executive in the performance of his duties and responsibilities hereunder, subject to any maximum annual limit and other
restrictions on such expenses set by the Board and to such reasonable substantiation and documentation as may be specified by the
Company from time to time.

 

(f)       Retirement
Benefits. Executive will be entitled to participate in the 401(k) plan and any other qualified or nonqualified deferred
compensation plans in which other executives of the Company generally are eligible to participate, in each case as in effect from
time to time and subject to the terms and conditions thereof.

 

5.       Termination
of Employment and Severance Benefits. The Executive’s employment hereunder shall terminate under the following circumstances:

 

(a)       Death.
In the event of the Executive’s death during the Term, the Executive’s employment shall immediately and automatically
terminate. In such event, the Company shall pay any Final Compensation to the Executive’s designated beneficiary or, if no
beneficiary has been designated by the Executive in writing, to his estate.

 

(b)       Disability.

 

(i)       The
Company may terminate the Executive’s employment hereunder, upon notice to the Executive, in the event that the Executive
becomes disabled through any illness, injury, accident or condition of either a physical or psychological nature and, as a result,
is unable to perform substantially all of his duties and responsibilities hereunder, notwithstanding the provision of any reasonable
accommodation, for a total of ninety (90) days, whether or not consecutive, during any period of three hundred and sixty-five (365)
consecutive calendar days. In the event of such termination, the Company shall have no further obligation to the Executive, other
than for payment of Final Compensation.

 

(ii)       The
Board may designate another employee to act in the Executive’s place during any period of the Executive’s disability.
Notwithstanding any such designation, the Executive shall continue to receive the Base Salary in accordance with Section 4(a) and
benefits in accordance with Section 4(d), to the extent permitted by the then-current terms of the applicable benefit plans, until
the Executive becomes eligible for disability income benefits under the Company’s disability income plan or until the termination
of his employment, whichever shall first occur.

 

 

 

    	 	2	 

     

    

 

(iii)       While
receiving disability income payments under the Company’s disability income plan, the Executive shall not be entitled to receive
any Base Salary under Section 4(a) hereof, but shall continue to participate in Company benefit plans in accordance with Section
4(d) and the terms of such plans, until the termination of his employment.

 

(iv)       If
any question shall arise as to whether during any period the Executive is disabled through any illness, injury, accident or condition
of either a physical or psychological nature so as to be unable to perform substantially all of his duties and responsibilities
hereunder, the Executive may, and at the request of the Company shall, submit to a medical examination by a physician selected
by the Company to whom the Executive or his duly appointed guardian, if any, has no reasonable objection to determine whether the
Executive is so disabled and such determination shall for the purposes of this Agreement be conclusive of the issue. If such question
shall arise and the Executive shall fail to submit to such medical examination, the Company’s determination of the issue
shall be binding on the Executive.

 

(c)       By
the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause at any time upon written
notice to the Executive setting forth in reasonable detail the nature of such Cause. The following, as determined by the Board
in its reasonable judgment, shall constitute “Cause” for termination:

 

(i)       The
Executive’s repeated failure or repeated refusal to perform (other than by reason of disability), or gross negligence in
the performance of, his material duties and responsibilities to the Company or any of its Affiliates;

 

(ii)       Material
breach by the Executive of any provision of this Agreement or any other agreement with the Company or any of its Affiliates or
any material policy of the Company or any of its Affiliates applicable to the Executive; provided that the first occurrence of
any particular breach shall not constitute Cause unless the Executive has failed to cure such breach within ten days after receiving
written notice from the Board stating the nature of such breach;

 

(iii)       The
Executive’s conviction of, or plea of guilty or nolo contendere to, any felony;

 

(iv)       The
Executive’s act of fraud;

 

(v)       The
Executive’s act or omission that, in the reasonable determination of the Company, indicates alcohol or drug abuse by the
Executive; or

 

(vi)       The
Executive’s act or personal conduct that, in the judgment of the Board (or a committee of the Board), gives rise to a material
risk of liability of the Executive or the Company under federal or applicable state law for discrimination, or sexual or other
forms of harassment, or other similar liabilities to subordinate employees.

 

Upon the giving of notice of termination of the Executive’s
employment hereunder for Cause, the Company shall have no further obligation to the Executive, other than for Final Compensation.

(d)       By
the Company Other Than for Cause. The Company may terminate the Executive’s employment hereunder other than for Cause
at any time upon written notice to the Executive.

 

(i)       In
the event of such termination without Cause, in addition to Final Compensation, subject to Section 5(d)(iii) and provided that
no benefits are payable to the Executive under a separate severance agreement as a result of such termination, then during the
period of six months following the date of termination, the Company shall continue to pay the Executive the Base Salary at the
rate in effect on the date of termination and, subject to any employee contribution applicable to the Executive on the date of
termination, shall continue to contribute (on a taxable basis) to the premium cost of the Executive’s participation in the
Company’s group medical and dental plans (unless prohibited by law), provided that the Executive is entitled to continue
such participation under applicable law and plan terms.

 

 

 

    	 	3	 

     

    

 

(ii)       Notwithstanding
and in lieu of the compensation set forth in Section 5(d)(i), in the event of a termination without Cause within 12 months following
a Change of Control, in addition to Final Compensation, subject to Section 5(d)(iii) and provided that no benefits are payable
to the Executive under a separate severance agreement as a result of such termination, then: (A) during the period of 12 months
following the date of termination, the Company shall continue to pay the Executive the Base Salary at the rate in effect on the
date of termination; (B) the vesting of a portion of the Executive’s outstanding equity awards granted by the Company shall
accelerate, with such acceleration to be equal to the greater of 50% of the unvested portion of all such outstanding awards or
the portion that would have vested over the twenty four (24) months from the termination date; and (C) subject to any employee
contribution applicable to the Executive on the date of termination, shall continue to contribute (on a taxable basis) to the premium
cost of the Executive’s participation in the Company’s group medical and dental plans (unless prohibited by law), provided
that the Executive is entitled to continue such participation under applicable law and plan terms. For purposes of this Agreement,
"Change in Control" shall mean: (x) an acquisition of any securities of the Company (the "Securities") by any
"person" (as the term "person" is used for purposes of Section 13(d) or Section 14(d) of the Securities Exchange
Act of 1934, as amended (the "1934 Act"), immediately after which such person has "beneficial ownership" (within
the meaning of Rule 13d-3 promulgated under the 1934 Act) ("Beneficial Ownership") of 50% or more of the shares of the
Company’s common stock (as determined on a fully-diluted, as-converted basis) without the approval of the Board; (y) a merger
or consolidation in which holders of the Capital Stock immediately prior to such transaction hold or are entitled to acquire, immediately
after the consummation of the merger or consolidation, less than 50% of the surviving entity’s common stock (as determined
on a fully-diluted, as-converted basis); or (z) the sale of all or substantially all of the Company’s assets. For purposes
of this Section 5(d)(ii), “Capital Stock” shall mean the Company’s common stock and any other Company securities
that are convertible into or exercisable for the Company’s common stock.

 

(iii)       Any
obligation of the Company to the Executive hereunder, other than for Final Compensation, is conditioned on the Executive signing
a timely and effective release of claims in the form provided by the Company (the “Employee Release”) and delivering
it to the Company by the deadline specified therein, and the Employee Release taking effect by its terms, within 60 calendar days
following the date his employment terminates. Any severance payments to which the Executive is entitled hereunder shall be payable
in accordance with the normal payroll practices of the Company, with the first payment, which shall be retroactive to the day immediately
following the date the Executive’s employment is terminated, being due and payable on the Company’s next regular payday
for executives that follows the expiration of 60 calendar days from the date the Executive’s employment terminates. The release
of claims required for separation benefits in accordance with this Section 5(d)(iii) creates legally binding obligations on the
part of the Executive and the Company and its Affiliates therefore advise the Executive to seek the advice of an attorney before
signing it.

 

(e)       By
the Executive for Good Reason. The Executive may terminate his employment hereunder for Good Reason by: (A) providing notice
to the Company specifying in reasonable detail the condition giving rise to the Good Reason no later than 30 days following the
occurrence of that condition; (B) providing the Company a period of 60 days to remedy the condition and so specifying in the notice;
and (C) terminating his employment for Good Reason within 30 days following the expiration of the period to remedy if the Company
fails to remedy the condition. The following, occurring without the Executive’s consent, shall constitute “Good Reason”
for termination by the Executive:

 

(i)       a
material reduction of the Executive’s regular responsibilities from those typically assigned to a Chief Development Officer
of a similarly situated biotechnology company;

 

(ii)       a
reduction in the Base Salary set forth in Section 4 hereof by more than 10% in any calendar year, unless such reduction is in proportion
with any Company-wide reductions in base salary for all executive officers of the Company;

 

(iii)       the
Company’s material breach of any material term of the Agreement; provided that the first occasion of any particular breach
shall not constitute such Good Reason unless the Company has failed to cure such breach within 60 days after receiving written
notice from the Executive stating the nature of such breach; or

 

(iv)       Relocation
of the Company’s principal executive offices of a distance in excess of 50 miles from its location at the Effective Date.

 

In the event of a termination of employment in accordance with
this Section 5(e), the Executive will be entitled to receive the same pay and benefits he would have been entitled to receive had
he been terminated by the Company other than for Cause in accordance with Section 5(d) above; provided that the Executive satisfies
all conditions to such entitlement, including without limitation the signing of the Employee Release as set forth in Section 5(d).

 

 

 

    	 	4	 

     

    

(f)       Timing
of Payments and Section 409A.

 

(i)       Notwithstanding
anything to the contrary in this Agreement, if at the time of the Executive’s termination of employment, the Executive is
a “specified employee,” as defined below, any and all amounts payable under this Section 5 on account of such separation
from service that would (but for this provision) be payable within six months following the date of termination, shall instead
be paid on the next business day following the expiration of such six (6) month period or, if earlier, upon the Executive’s
death; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation
Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined
by the Company in its reasonable good faith discretion); (B) benefits which qualify as excepted welfare benefits pursuant to Treasury
regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A of
the Internal Revenue Code (“Section 409A”).

 

(ii)       For
purposes of this Agreement, all references to “termination of employment” and correlative phrases shall be construed
to require a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations after giving
effect to the presumptions contained therein), and the term “specified employee” means an individual determined by
the Company to be a specified employee under Treasury regulation Section 1.409A-1(i).

 

(iii)       Each
payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under
this Agreement is to be treated as a right to a series of separate payments.

 

(iv)       The
Executive’s right to reimbursement for business expenses hereunder shall be subject to the following additional rules: (i)
the amount of expenses eligible for reimbursement during any calendar year shall not affect the expenses eligible for reimbursement
in any other taxable year; (ii) reimbursement shall be made not later than December 31 of the calendar year following the calendar
year in which the expense was incurred; and (iii) the right to reimbursement is not subject to liquidation or exchange for any
other benefit.

 

(v)In no event shall the Company
have any liability relating to any payment or benefit under this Agreement failing to comply with, or be exempt from, the requirements
of Section 409A.

 

6.       Effect
of Termination. The provisions of this Section 6 shall apply to any termination of the Executive’s employment hereunder:

 

(a)       
The Company shall pay to the Executive: (i) any Base Salary earned but not paid during the final payroll period of the Executive’s
employment through the date of termination; (ii) pay for any paid time off earned but not used through the date of termination;
(iii) any bonus compensation awarded for the year preceding that in which termination occurs, but unpaid on the date of termination;
and (iv) any business expenses incurred by the Executive but un-reimbursed on the date of termination, provided that such expenses
and required substantiation and documentation are submitted within 60 days of termination and that such expenses are reimbursable
under Company policy (all of the foregoing, “Final Compensation”). The Company shall have no further obligation to
the Executive hereunder except as set forth in Section 5(d) or Section 5(e). Any Base Salary or pay for earned but unused paid
time off shall be payable at the time provided by applicable law. Any bonus due for the preceding year shall be payable at the
time provided for at the time such bonus is awarded. Any business expenses shall be payable not later than 90 days following the
date of termination.

 

(b)       Payment
by the Company of Final Compensation and any Base Salary and contributions to the cost of the Executive’s continued participation
in the Company’s group health and dental plans that may be due the Executive in each case under the applicable termination
provision of Section 5 shall constitute the entire obligation of the Company to the Executive hereunder. The Executive shall promptly
give the Company notice of all facts necessary for the Company to determine the amount and duration of its obligations in connection
with any termination pursuant to Section 5(d) or Section 5(e) hereof.

 

(c)       Except
for any right of the Executive to continue medical and dental plan participation in accordance with applicable law, benefits shall
terminate pursuant to the terms of the applicable benefit plans based on the date of termination of the Executive’s employment
without regard to any continuation of Base Salary or other payment to the Executive following such date of termination.

 

 

 

    	 	5	 

     

    

 

(d)       Provisions
of this Agreement shall survive any termination if so provided herein or if necessary or desirable to accomplish the purposes of
other surviving provisions, including without limitation the obligations of the Executive under Sections 7, 8 and 9 hereof. The
obligation of the Company to make payments to or on behalf of the Executive under Section 5(d) or Section 5(e) hereof is expressly
conditioned upon the Executive’s continued full performance of obligations under Sections 7, 8 and 9 hereof. The Executive
recognizes that, except as expressly provided in Section 5(d) or Section 5(e), no compensation is earned after termination of employment.

 

7.       Confidential
Information.

 

(a)       The
Executive acknowledges that the Company and its Affiliates continually develop Confidential Information, that the Executive may
develop Confidential Information for the Company or its Affiliates and that the Executive may learn of Confidential Information
during the course of employment. The Executive will comply with the policies and procedures of the Company and its Affiliates for
protecting Confidential Information and shall not disclose to any Person or use, other than as required by applicable law or for
the proper performance of his duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained
by the Executive incident to his employment or other association with the Company or any of its Affiliates. The Executive understands
that this restriction shall continue to apply after his employment terminates, regardless of the reason for such termination. The
confidentiality obligation under this Section 7 shall not apply to information which is generally known or readily available to
the public at the time of disclosure or becomes generally known through no wrongful act on the part of the Executive or any other
person having an obligation of confidentiality to the Company or any of its Affiliates. Notwithstanding the foregoing, if Executive
makes a confidential disclosure of a trade secret or other Confidential Information to a government official or an attorney for
the sole purpose of reporting a suspected violation of law, or in a court filing under seal, Executive shall not be held liable
under this Agreement or under any federal or state trade secret law for such a disclosure.

 

(b)       All
documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the
Company or its Affiliates and any copies, in whole or in part, thereof (the “Documents”), whether or not prepared by
the Executive, shall be the sole and exclusive property of the Company and its Affiliates. The Executive shall safeguard all Documents
and shall surrender to the Company at the time his employment terminates, or at such earlier time or times as the Board or its
designee may specify, all Documents then in the Executive’s possession or control.

 

8.       Assignment
of Rights to Intellectual Property. The Executive shall promptly and fully disclose all Intellectual Property to the Company.
The Executive hereby assigns and agrees to assign to the Company (or as otherwise directed by the Company) the Executive’s
full right, title and interest in and to all Intellectual Property. The Executive agrees to execute any and all applications for
domestic and foreign patents, copyrights or other proprietary rights and to do such other acts (including without limitation the
execution and delivery of instruments of further assurance or confirmation) requested by the Company to assign the Intellectual
Property to the Company and to permit the Company to enforce any patents, copyrights or other proprietary rights to the Intellectual
Property. The Executive will not charge the Company for time spent in complying with these obligations. All copyrightable works
that the Executive creates shall be considered “work made for hire” and shall, upon creation, be owned exclusively
by the Company. The Executive’s obligation to assist the Company in obtaining and enforcing patents for Intellectual Property
in any and all countries shall continue beyond the termination of the Executive’s employment with the Company, but the Company
shall compensate the Executive at a reasonable, standard hourly rate following such termination for time directly spent by Executive
at the Company’s request for such assistance.

 

9.       Restricted
Activities. The Executive agrees that the following restrictions on his activities during and after his employment are necessary
to protect the good will, Confidential Information, trade secrets and other legitimate interests of the Company and its Affiliates:

 

(a)       During
the Term, the Executive will not undertake any outside activity, whether or not Competitive with the business of the Company or
its Affiliates that could reasonably give rise to a conflict of interest or otherwise interfere with his duties and obligations
to the Company or any of its Affiliates.

 

 

 

    	 	6	 

     

    

 

(b)       During
the Term and for the Restricted Period, the Executive shall not, directly or indirectly, whether as owner, partner, investor, consultant,
agent, employee, co-venturer or otherwise: (i) engage in any Competitive activity within the United States or any other country
in which the Company has conducted discovery, development or commercialization activities for any Product or has sought patent
protection for any Product, in either case as of the date of such termination; or (ii) undertake any planning for any Competitive
business. Specifically, but without limiting the foregoing, the Executive agrees not to engage in any manner in any activity that
is directly or indirectly Competitive or potentially Competitive and further agrees not to work or provide services, in any capacity,
whether as an employee, independent contractor or otherwise, whether with or without compensation, to any Person who is engaged
in any business that is Competitive. The foregoing, however, shall not prevent the Executive’s passive ownership of one percent
(1%) or less of the equity securities of any publicly traded company. For purposes of this Agreement: (A) the “Restricted
Period” shall be the six months following the date of termination; and (B) the term “Competitive” shall mean
either (i) the discovery, development or commercialization of any therapeutics or diagnostics utilizing any technology relating
to the interference of RNA or otherwise relating to the expression, or non-expression, of targeted genes or genetic pathways; or
(ii) the discovery, development or commercialization of any therapeutics or diagnostics for the same or related biological target
for the treatment of the same diseases, disorders or conditions using technology relating to the interference of RNA or otherwise
relating to the expression, or non-expression, of targeted genes or genetic pathways. During the Restricted Period, the Executive
will not directly or indirectly (a) solicit or encourage any customer of the Company or any of its Affiliates to terminate or diminish
its relationship with them; or (b) seek to persuade any such customer or prospective customer of the Company or any of its Affiliates
to conduct with anyone else any business or activity which such customer or prospective customer conducts or could conduct with
the Company or any of its Affiliates; provided that these restrictions shall apply (y) only with respect to those Persons who are
or have been a customer of the Company or any of its Affiliates at any time within the immediately preceding two-year period or
whose business has been solicited on behalf of the Company or any of the Affiliates by any of their officers, employees or agents
within said two year period, other than by form letter, blanket mailing or published advertisement; and (z) only if the Executive
has performed work with such Person during his employment with the Company or one of its Affiliates or been introduced to, or otherwise
had contact with, such Person as a result of his employment or other associations with the Company or one of its Affiliates or
has had access to Confidential Information which would assist in the Executive’s solicitation of such Person.

 

(c)       During
the Restricted Period, the Executive will not, and will not assist any other Person to (a) hire or solicit for hiring any employee
of the Company or any of its Affiliates or seek to persuade any employee of the Company or any of its Affiliates to discontinue
employment; or (b) solicit or encourage any independent contractor providing services to the Company or any of its Affiliates to
terminate or diminish its relationship with them. For the purposes of this Agreement, an “employee” of the Company
or any of its Affiliates is any person who was such at any time within the preceding two years.

 

10.       Notification
Requirement. Until 45 days after the conclusion of the Restricted Period, the Executive shall give notice to the Company of
each new business activity he undertakes, at least ten days prior to beginning any such activity. Such notice shall state the name
and address of the Person for whom such activity is undertaken and the nature of the Executive’s business relationship(s)
and position(s) with such Person. The Executive shall provide the Company with such other pertinent information concerning such
business activity as the Company may reasonably request in order to determine the Executive’s continued compliance with his
obligations under Sections 7, 8 and 9 hereof.

 

11.       Enforcement
of Covenants. The Executive acknowledges that he has carefully read and considered all the terms and conditions of this Agreement,
including the restraints imposed upon him pursuant to Sections 7, 8 and 9 hereof. The Executive agrees without reservation that
each of the restraints contained herein is necessary for the reasonable and proper protection of the good will, Confidential Information,
trade secrets and other legitimate interests of the Company and its Affiliates; that each and every one of those restraints is
reasonable in respect to subject matter, length of time and geographic area; and that these restraints, individually or in the
aggregate, will not prevent him from obtaining other suitable employment during the period in which the Executive is bound by these
restraints. The Executive further agrees that he will never assert, or permit to be asserted on his behalf, in any forum, any position
contrary to the foregoing. The Executive further acknowledges that, were he to breach any of the covenants contained in Sections
7, 8 or 9 hereof, the damage to the Company would be irreparable. The Executive therefore agrees that the Company, in addition
to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened
breach by the Executive of any of said covenants, without having to post bond and to recover its reasonable attorneys’ fees
and costs incurred in securing such relief. The Executive agrees that the Restricted Period shall be tolled, and shall not run,
during any period of time in which he is in violation of the terms thereof, in order that the Company and its Affiliates shall
have all of the agreed-upon temporal protection recited herein. The parties further agree that, in the event that any provision
of Section 7, 8 or 9 hereof shall be determined by any court of competent jurisdiction to be unenforceable by reason of its being
extended over too great a time, too large a geographic area or too great a range of activities, such provision shall be deemed
to be modified to permit its enforcement to the maximum extent permitted by law.

 

 

 

    	 	7	 

     

    

 

12.       Conflicting
Agreements. The Executive hereby represents and warrants that the execution of this Agreement and the performance of his obligations
hereunder will not breach or be in conflict with any other agreement to which the Executive is a party or is bound and that the
Executive is not now subject to any covenants against competition or similar covenants or any court order or other legal obligation
that would affect the performance of his obligations hereunder. The Executive will not disclose to or use on behalf of the Company
any proprietary information of a third party without such party’s consent.

 

13.       Definitions.
Words or phrases which are initially capitalized or are within quotation marks shall have the meanings provided in this Section
and as provided elsewhere herein. For purposes of this Agreement, the following definitions apply:

 

(a)       “Affiliates”
means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where
control may be by management authority, contract or equity interest.

 

(b)       “Confidential
Information” means any and all information of the Company and its Affiliates that is not generally known by those with whom
the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete
or do business and any and all information, publicly known in whole or in part or not, which, if disclosed by the Company or any
of its Affiliates would assist in competition against them. Confidential Information includes without limitation such information
relating to (i) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates;
(ii) the Products; (iii) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates;
(iv) the identity and special needs of the customers of the Company and its Affiliates; and (v) the people and organizations with
whom the Company and its Affiliates have business relationships and the nature and substance of those relationships. Confidential
Information also includes any information that the Company or any of its Affiliates has received, or may receive hereafter, belonging
to customers or others with any understanding, express or implied, that the information would not be disclosed.

 

(c)       “Intellectual
Property” means inventions, discoveries, developments, methods, processes, compositions, works, concepts and ideas (whether
or not patentable or copyrightable or constituting trade secrets) conceived, made, created, developed or reduced to practice by
the Executive (whether alone or with others, whether or not during normal business hours or on or off Company premises) during
the Executive’s employment and during the period of six months immediately following termination of his employment that relate
to either the Products or any prospective activity of the Company or any of its Affiliates or that make use of Confidential Information
or any of the equipment or facilities of the Company or any of its Affiliates.

 

(d)       “Person”
means an individual, a corporation, a limited liability company, an association, a partnership, an estate, a trust and any other
entity or organization, other than the Company or any of its Affiliates.

 

(e)       “Products”
mean all products and product candidates planned, researched, developed, tested, manufactured, sold, licensed, leased or otherwise
distributed or put into use by the Company or any of its Affiliates, together with all related services provided or planned by
the Company or any of its Affiliates, during the Executive’s employment with the Company or any of its Affiliates.

 

14.       Withholding.
All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the
Company under applicable law.

 

15.       Assignment.
Neither the Company nor the Executive may make any assignment of this Agreement or any interest herein, by operation of law or
otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations
under this Agreement without the consent of the Executive in the event that the Executive is transferred to a position with any
of the Affiliates or in the event that the Company shall hereafter effect a reorganization, consolidate with, or merge into, any
Person or transfer all or substantially all of its properties or assets to any Person. This Agreement shall inure to the benefit
of and be binding upon the Company and the Executive, their respective successors, executors, administrators, heirs and permitted
assigns.

 

 

 

    	 	8	 

     

    

 

16.       Severability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of
this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

17.       Waiver.
No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of either
party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

18.       Notices.
Any and all notices, requests, demands and other communications provided for by this Agreement shall be in writing and shall be
effective when delivered in person, consigned to a reputable national courier service or deposited in the United States mail, postage
prepaid, registered or certified, and addressed to the Executive at his last known address on the books of the Company or, in the
case of the Company, at its principal place of business, attention of the Chairman of the Board, or to such other address as either
party may specify by notice to the other actually received.

 

19.       Entire
Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior communications, agreements
and understandings, written or oral, with respect to the terms and conditions of the Executive’s employment with the Company,
other than any obligations owed to the Company or its predecessor with respect to confidentiality, non-competition, intellectual
property, and proprietary information, all of which shall continue in force.

 

20.       Amendment.
This Agreement may be amended or modified only by a written instrument signed by the Executive and by an expressly authorized representative
of the Company.

 

21.       Headings.
The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any
provision of this Agreement.

 

22.       Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall
constitute one and the same instrument.

 

23.       Governing
Law. This is a Massachusetts contract and shall be construed and enforced under and be governed in all respects by the laws
of the Commonwealth of Massachusetts, without regard to the conflict of laws principles thereof.

 

 

 

[Signature page follows immediately.]

 

 

 

    	 	9	 

     

    

 

IN WITNESS WHEREOF, this Agreement has been
executed as a sealed instrument by the Company, by its duly authorized representative, and by the Executive, as of the date first
above written.

 

 

	THE EXECUTIVE:	PHIO PHARMACEUTICALS CORP.
	 	 
	 	 
	 	 
	By: /s/ John Barrett	By:  /s/ Gerrit Dispersyn
	      Name: John Barrett, Ph.D.	        Name: Gerrit Dispersyn, Dr. Med. Sc.
	 	                    Title: President & CEO

 

 

 

 

 

 

 

 

 

 

[Signature Page to John Barrett Employment
Agreement]

 

 

    	 	10emma-ex43_39.htm

Exhibit 4.3

 

THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). NO SALE OR DISPOSITION MAY BE AFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN APPLICABLE EXEMPTION THEREFROM.

 

EMMAUS LIFE SCIENCES, INC.

Convertible Promissory Note

Principal Amount:   US$213,300.25             Loan Date:      02/02/2019 

Currency:U.S. DollarsTerm:                 One Year  

Interest Rate:10% Loan Due Date:   02/02/2020 

Interest Payment Period:  Interest is accrued and paid upon Loan Due Date

Lender:               Hiromi Saito                                                                                                                             

FOR VALUE RECEIVED, Emmaus Life Sciences, Inc., a Delaware corporation, located at 21250 Hawthorne Blvd., Suite 800, Torrance, CA  90503 (“Borrower”) hereby promises to pay to the order of Lender the sum of the Principal Amount in the stated Currency, together with any accrued interest at the stated Interest Rate, under the following terms and conditions of this Convertible Promissory Note (“Note”).

 

1. Terms of Repayment (Balloon Payment): The entire unpaid Principal Amount and any accrued interest shall become immediately due and payable upon the stated Loan Due Date. Simple interest at the stated Interest Rate will accrue on the outstanding Principal Amount commencing on the stated Loan Date. 

 

2. Prepayment: This Note may be prepaid in whole or in part at any time without premium or penalty upon ten days advance written notice by Borrower to Lender. All prepayments shall first be applied to interest, and then to principal payments.

 

3. Place of Payment: All payments due under this Note shall be sent to the Lender’s address, as noted in Attachment 1 hereto, or at such other place as the Lender or subsequently assigned holder (“Holder”) of this Note may designate in writing in the future.

 

4. Conversion:

 

(a)Mandatory Conversion:   Upon the listing of shares of common stock of the Borrower (“Common Stock”) on the OTC market or trading on a national securities exchange (the “Qualification”), (i) the entire outstanding Principal Amount of this Note shall automatically be converted into the number of shares of Common Stock determined by dividing (x) the outstanding Principal Amount of this Note by a fixed share price of $4.50 (subject to appropriate adjustment in the event of any stock splits, stock dividends, recapitalizations and similar transactions with respect 

 

 

to the capital stock of Borrower). Within thirty days of such closing, all accrued and unpaid interest on the Note, if any, will be paid to the Holder in cash.  

 

The Borrower shall notify the holder of this Note at least seven (7) calendar days following the Qualification. Thereafter, the holder of this Note shall deliver this Note to the Borrower and, as soon as reasonably practicable thereafter, the Borrower shall issue and deliver to the holder of this Note a certificate or certificates for the number of full shares of Common Stock issuable upon the conversion of this Note, and provision shall be made for any fraction of a share as provided in Section 4(b) below.  At the time of the Qualification, and provided that the Borrower has complied fully with all of its obligations under this Section 4(a), the holder of this Note shall not have any further rights under this Note (including the right to receive payment of principal or interest hereunder) other than those rights set forth in this Section 4.

 

(b)Fractional Shares:  No fractional shares or scrip shall be issued upon conversion of this Note.  The number of full shares of Common Stock issuable upon conversion of this Note shall be computed on the basis of the aggregate value of outstanding principal of and, as applicable in accordance with the terms of this Section 4, accrued interest on this Note so surrendered.  The value of any fractional shares of Common Stock shall be paid in cash.

 

(c)Conversion at the Election of the Holder:  If the mandatory conversion is not executed, by or after the first anniversary of the Loan Date, Lender may by giving written Notice of Conversion to the Borrower in the form attached hereto as Exhibit A, elect to convert some or all of the unpaid Principal Amount, including up to all the interest accrued and unpaid thereon, into a number of shares of Common Stock determined by dividing (x) the outstanding Principal Amount of this Note by (y) the Conversion Price Per Share. As used in this Section 4(c), “Conversion Price Per Share” means $4.50 per share of Common Stock (subject to appropriate adjustment in the event of any stock splits, stock dividends, recapitalizations and similar transactions with respect to the capital stock of Borrower). Within two weeks following receipt of such Notice of Conversion, Borrower shall deliver to Lender one or more original stock certificates representing the full number of shares of Common Stock issuable upon such conversion, and provision shall be made for any fraction of a share as provided in Section 4(b) above. Upon such conversion, and provided that the Borrower has complied fully with all of its obligations under this Section 4(c), the holder of this Note shall not have any further rights under this Note (including the right to receive payment of principal or interest hereunder) other than those rights set forth in this Section 4.

 

5. Default: In the event of default, the Borrower agrees to pay all costs and expenses incurred by the Lender, including all reasonable attorney fees as permitted by law for the collection of this Note upon default.

 

6. Acceleration of Debt: If the Borrower (i) fails to make any payment due under the terms

of this Note or seeks relief under the U.S. Bankruptcy Code, (ii) fails to deliver shares to the Lender by the deadline set forth in Section 4 hereof, (iii) suffers an involuntary petition in bankruptcy or receivership that is not vacated within thirty (30) days, (iv) consents to the appointment of a receiver, trustee, assignee, liquidator or similar official or such appointment is not discharged or stayed within 30 days, (v) makes a general assignment for the benefit of its creditors or (vi) admits in writing that it is generally unable to pay its debts as they become due, the entire balance of this Note and any interest accrued thereon shall be immediately due and payable to the holder of this Note.

 

 

 

7. Modification: No modification or waiver of any of the terms of this Note shall be allowed unless by written agreement signed by the Borrower and the Lender. No waiver of any breach or default hereunder shall be deemed a waiver of any subsequent breach or default of the same or similar nature.

 

8. Complete Note: This Note is the complete and exclusive statement of agreement of the Borrower and Lender with respect to matters in this Note. This Note replaces and supersedes all prior written or oral agreements or statements by and among the Borrower and Lender with respect to the matters covered by it. No representation, statement, condition or warranty not contained in this Note is binding on either the Borrower or Lender. Each Holder of this Note, by its acceptance hereof, agrees to be bound by, and shall be entitled to the benefits of, the terms set forth herein.

 

9. Transfer of the Note: 

 

(a)  Subject to Section 9(b) hereof, this Note may be transferred, in whole or in part, at any time or from time to time, by the Lender. The Borrower hereby agrees to remain bound by the terms of this Note subsequent to any such transfer, and agrees that the terms of this Note may be fully enforced by any subsequent holder of this Note. If this Note is to be transferred, the Lender shall surrender this Note to the Borrower, together with such additional documentation as the Lender may reasonably request, whereupon the Borrower will forthwith issue and deliver upon the order of the Lender a new Note registered as the Lender may request, representing the outstanding Principal Amount being transferred by the Lender and, if less then the entire outstanding Principal Amount is being transferred, a new Note to the Lender representing the outstanding Principal Amount not being transferred. The person in whose name this Note or any new Note issued in replacement hereof shall be registered shall be deemed and treated as the owner and holder thereof, and the Borrower shall not be affected by any notice or knowledge to the contrary except as provided in this Section 9(a). This Note may not be transferred by the Borrower, by operation of law or otherwise, without the prior written consent of the Lender. 

 

(b) Lender acknowledges and agrees that this Note has been acquired for investment and has not been registered under the securities laws of the United States of America or any state thereof.  Accordingly, notwithstanding Section 9(a), neither this Note nor any interest thereon may be offered for sale, sold or transferred in the absence of registration under applicable federal and state securities laws or an opinion of counsel of the Holder reasonably satisfactory to the Borrower that such registration is not required.  

 

10. Lost, Stolen or Mutilated Note:  Upon receipt by the Borrower of evidence reasonably satisfactory to the Borrower of the loss, theft, destruction or mutilation of this Note, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Lender to the Borrower in customary form and, in the case of mutilation, upon surrender and cancellation of this Note, the Borrower shall execute and deliver to the Lender a new Note representing the outstanding Principal Amount and accrued and unpaid interest thereon.

 

11. Remedies:  The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Lender’s right to pursue actual and consequential damages for any failure by the Borrower to comply with the terms of this Note.  

 

 

 

12. Severability of Provisions: If any portion of this Note is deemed unenforceable, all other provisions of this Note shall remain in full force and effect.

 

13. Choice of Law: All terms and conditions of this Note shall be interpreted under the laws

of California, U.S.A., without regard to conflict of law principles.

 

 

 

Signed Under Penalty of Perjury, this   2nd   day of  February,  2019

 

Emmaus Life Sciences, Inc.

 

 

 

_______________________________________

By: Yutaka Niihara, MD, MPH, Chairman and CEO

 

 

Acknowledged and accepted by Lender

 

 

 

_______________________________________

By: Hiromi Saito

 

 

 

ATTACHMENT 1

 

Lender’s Name: Hiromi Saito

 

Lender’s Address: 

 

 

 

EXHIBIT A

NOTICE OF CONVERSION

(To be executed by the Lender in order to convert the Note)

		
	
TO:  Emmaus Life Sciences, Inc.
	
 

 

	
The undersigned hereby irrevocably elects to convert $
	
 of the principal amount of the Note issued to the Lender by Emmaus Life Sciences, Inc. (the “Company”) into shares of Common Stock of the Company according to the conditions stated therein, as of the Conversion Date written below.

		
	
Conversion Date:
	
 

	
Applicable Conversion Price:
	
 

	
Signature:
	
 

	
Name:
	
 

	
Address:
	
 

	
Amount to be converted:
	
$  

	
Amount of Note unconverted:
	
$  

	
Number of shares of Common Stock to be issued:
	
 

	
Please issue the shares of  Common Stock in the following name and to the following address:
	
 

	
Address:
	
 

	
Address:
	
 

	
Phone Number:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]